Andrew Polson is a Principal Scientist at Genentech where he leads the development of antibody-drug conjugates and other antibody based cancer therapeutics. On these topics Andrew has over 13 corresponding author publications and is an inventor on over 15 issued patents.  Prior to his 18 years at Genentech he was a postdoctoral fellow in virology at the University of California, San Francisco.  He received his Ph.D. in…Read more

Dr. Gilles Gallant is an oncology expert with broad biotechnology and pharmaceutical experience in strategic cancer drug development, evaluation, and innovations. Gillesjoined DaiichiSankyo,Inc. (Basking Ridge, New Jersey) in 2017 as Vice President, Global Team Leader, Oncology Research &Development. Daiichi SankyoCancer Enterprise’s mission is to leverage world-class, innovative science and push beyond traditional thinking to create…Read more

Read more